###begin article-title 0
The CXC-Chemokine CXCL4 Interacts with Integrins Implicated in Angiogenesis
###end article-title 0
###begin p 1
Conceived and designed the experiments: SA AB. Performed the experiments: SA KB. Analyzed the data: SA AB. Contributed reagents/materials/analysis tools: AB NK. Wrote the paper: SA AB. Designed the study: SA.
###end p 1
###begin p 2
###xml 843 851 804 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 590 595 <span type="species:ncbi:9606">human</span>
The human CXC-chemokine CXCL4 is a potent inhibitor of tumor-induced angiogenesis. Considering that CXCL4 is sequestered in platelet alpha-granules and released following platelet activation in the vicinity of vessel wall injury, we tested the hypothesis that CXCL4 might function as a ligand for integrins. Integrins are a family of adhesion receptors that play a crucial role in angiogenesis by regulating early angiogenic processes, such as endothelial cell adhesion and migration. Here, we show that CXCL4 interacts with alphavbeta3 on the surface of alphavbeta3-CHO. More importantly, human umbilical vein endothelial cells adhere to immobilized CXCL4 through alphavbeta3 integrin, and also through other integrins, such as alphavbeta5 and alpha5beta1. We further demonstrate that CXCL4-integrin interaction is of functional significance in vitro, since immobilized CXCL4 supported endothelial cell spreading and migration in an integrin-dependent manner. Soluble CXCL4, in turn, inhibits integrin-dependent endothelial cell adhesion and migration. As a whole, our study identifies integrins as novel receptors for CXCL4 that may contribute to its antiangiogenic effect.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 264 267 264 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Folkman1">[1]</xref>
###xml 367 370 367 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Folkman2">[2]</xref>
###xml 436 439 436 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Folkman3">[3]</xref>
###xml 599 602 595 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Levine1">[4]</xref>
###xml 721 729 717 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 729 732 725 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Maione1">[5]</xref>
###xml 733 736 729 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 741 748 737 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 748 751 744 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Maione1">[5]</xref>
###xml 753 756 749 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 757 760 753 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sharpe1">[8]</xref>
###xml 801 804 797 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Tanaka1">[9]</xref>
###xml 805 809 801 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Bello1">[11]</xref>
###xml 825 829 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Kolber1">[12]</xref>
###xml 829 836 825 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 928 931 924 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sharpe1">[8]</xref>
###xml 932 936 928 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Kolber1">[12]</xref>
###xml 1030 1034 1026 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vivo</italic>
###xml 1043 1046 1039 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Maione1">[5]</xref>
Angiogenesis is the formation of new capillaries from preexisting blood vessels. Angiogenesis plays an important role in physiologic processes such as wound healing and in disease progression such as cancer, diabetic retinopathy and various inflammatory disorders [1]. In particular, the expansion of solid tumors and other cancers critically depends on angiogenesis [2], making anti-angiogenesis strategies relevant for cancer therapy [3]. CXCL4, a CXC-chemokine, is synthesized predominantly in megakaryocytes, sequestered in alpha-granules of platelets, and released upon activation of platelets [4]. CXCL4 and the peptide derived from its carboxyl-terminal domain (CXCL4/CTF) display a strong antiangiogenic activity in vitro[5]-[7] and in vivo[5], [7]-[8]. They suppress growth of various tumors [9]-[11] and metastasis [12]in vivo. This effect is related to their antiangiogenic action and not to tumor cell proliferation [8]-[12]. Although CXCL4 is one of the first agents discovered to have an antiangiogenic action in ex-vivo systems [5], the specific receptor mechanisms that transduce the antiangiogenic signal of CXCL4 are still poorly understood.
###end p 4
###begin p 5
###xml 553 557 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Davis1">[13]</xref>
###xml 605 612 605 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 787 791 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Brooks1">[14]</xref>
###xml 793 797 786 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Brooks2">[15]</xref>
###xml 1069 1076 1034 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1094 1098 1059 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Friedlander1">[16]</xref>
###xml 1319 1323 1270 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Kim1">[17]</xref>
###xml 1401 1404 1352 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Folkman3">[3]</xref>
###xml 1289 1294 <span type="species:ncbi:9606">human</span>
Angiogenesis depends on vascular endothelial cell proliferation, migration and invasion. A family of adhesion receptors known as integrin receptors tightly regulates these early angiogenic processes. Indeed, integrins are the major adhesion receptors used by endothelial cells undergoing angiogenesis to interact with their extracellular matrix (ECM). This interaction causes spreading of endothelial cells with cytoskeleton re-organization events necessary for cells to invade ECM, to proliferate, to migrate and to ultimately form new tubular vessels [13]. The integrin-dependency of tumor angiogenesis in vivo is evidenced by the fact that antagonists of the alphavbeta3 integrin, which are highly expressed in angiogenic endothelium, suppress tumor growth by inhibiting angiogenesis [14], [15]. Furthermore, the functionally and structurally homologous alphavbeta5 has been implicated in angiogenesis under certain conditions and selective antagonists of alphavbeta5 or dual antagonists of alphavbeta3 and alphavbeta5 integrins inhibit VEGF-stimulated angiogenesis in vivo in animal models [16]. Finally, the alpha5beta1 integrin was shown to play a crucial role in angiogenesis and selective antagonists of alpha5beta1 integrin block tumor angiogenesis, thereby causing regression of human tumors in animal models [17]. Several integrin inhibitors are currently tested as therapeutics for cancer [3].
###end p 5
###begin p 6
###xml 128 132 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Fukami1">[18]</xref>
###xml 178 185 174 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 219 223 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hansell1">[19]</xref>
###xml 225 229 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Borgstrom1">[20]</xref>
Taking into account that CXCL4 is released from the alpha-granules of activated platelets in the vicinity of vessel wall injury [18] and that CXCL4 targets the endothelial cells in vivo that undergo active angiogenesis [19], [20], we examined the possibility that CXCL4 might function as a ligand for integrins. We show here that CXCL4 binds to alphavbeta3 and to some extent to alphavbeta5 and alpha5beta1 integrins on the surface of endothelial cells. The CXCL4-integrin interaction is of functional significance, since CXCL4 modulated endothelial cell functions, such as spreading and migration through integrins. Taken together with the established importance of integrin in tumor angiogenesis, this study provides a new mechanistic context for the function of CXCL4 as an angiogenesis inhibitor.
###end p 6
###begin title 7
Results
###end title 7
###begin title 8
###xml 41 46 <span type="species:ncbi:9606">human</span>
1/Immobilized CXCL4 or CXCL4/CTF induces human endothelial cell spreading, and focal adhesion kinase (FAK) phosphorylation
###end title 8
###begin p 9
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Schwartz1">[21]</xref>
###xml 339 343 339 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Leavesley1">[22]</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Stromblad1">[23]</xref>
###xml 505 511 505 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>
###xml 926 929 926 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Maione1">[5]</xref>
###xml 930 933 930 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 947 953 947 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>
###xml 1419 1425 1419 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>
Integrin-mediated cell attachment on cognate integrin ligands, such as ECM proteins, results in cell spreading, focal adhesion formation, and tyrosine phosphorylation of intracellular proteins [21]. When integrin inhibitors such as antibodies are immobilized on a substrate, they act as agonist and similarly activate intracellular events [22], [23]. To examine whether immobilized CXCL4 would function as an integrin agonist, HUVECs were plated on coverslips that had been coated with CXCL4. As shown in Fig. 1, immobilized CXCL4 similar to natural integrin ligands fibrinogen or fibronectin, promoted endothelial cells spreading, focal adhesion and stress fibers formation. Furthermore, to determine whether the C-terminus of CXCL4 exhibited similar effects, we used a synthetic peptide encompassing amino-acid sequence 47-70 (CXCL4/CTF). Previous data showed that the peptide retains full anti-angiogenic activity of CXCL4 [5]-[7]. As shown in Fig. 1, CXCL4/CTF demonstrated similar effects on endothelial cell spreading, focal adhesion and stress fibers formation as full length CXCL4. Furthermore, when HUVECs are plated on a -scrambled peptide containing amino acides derived from CXCL4/CTF (CXCL4/CTF-S) (that does not exhibit anti-angiogenic activity), or on polylysine (to which cells adhere in an integrin-independent manner), they remained round, and failed to spread and to induce focal adhesion formation (Fig. 1).
###end p 9
###begin title 10
###xml 40 45 <span type="species:ncbi:9606">human</span>
Immobilized CXCL4 or CXCL4/CTF promotes human umbilical vein endothelial cells (HUVECs) spreading, focal adhesion and stress fiber formation.
###end title 10
###begin p 11
(A) Analysis of spreading, focal adhesion and stress fibers. HUVECs were plated for 4h on coverslips that had been coated with (25 microg/ml) CXCL4, (25 microg/ml) CXCL4/CTF, (100 microg/ml) fibrinogen, (25 microg/ml), CXCL4/CTF-S and (100 microg/ml) poly-D-lysine. After washing, the cells are fixed. The degree of cell spreading is seen from the phase contrast micrographs (left side) Then the cells were permeabilized and stained to visualize focal adhesion (vinculin staining, green), and actin stress fibers (Rhodamin-Phalloidin staining, red) by confocal microscopy (right side). (B) Analysis of tyrosine phosphorylation of FAK. Effect of HUVEC cell adhesion to CXCL4 or CXCL4/CTF on tyrosine phosphorylation of FAK. HUVECs were maintained in suspension for 60 min (BSA, lane 1) or allowed to attach to integrins ligand (fibrinogen, lane 4) or CXCL4 (lane 2) or CXCL4/CTF (lane 3). Cells lysates containing equal amounts of protein were immunoprecipitated with anti-FAK antibody. One half of immunoprecipitates was subjected to immunoblotting with anti-phosphotyrosine mAbs, 4G10, and PY20, and the other half was probed with mAb anti-FAK.
###end p 11
###begin p 12
###xml 312 319 312 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1A</xref>
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1B</xref>
Focal adhesion kinase (FAK) is a 125 kDa cytoplasmic tyrosine kinase colocalised with integrins at focal adhesion contacts and rapidly becomes phosphorylated and activated upon integrin mediated cell adhesion. As shown above, immobilized CXCL4 or CXCL4/CTF promotes cell spreading with focal adhesion formation (Fig. 1A). We tested whether these events are sufficient to activate (tyrosine phosphorylation) FAK. As shown in (Fig. 1B), attachment of HUVECs to immobilized CXCL4 or CXCL4/CTF, similar to fibronectin, induced tyrosine phosphorylation of FAK. As expected, attached cell to polylysine, similar to cells in suspension, failed to tyrosine phosphorylate FAK. Taken together, these results suggest that immobilized CXCL4 or CXCL4/CTF serves as an adhesive ligand to endothelial cells and activates postligand binding events downstream of integrins.
###end p 12
###begin title 13
2/CXCL4 or CXCL4/CTF mediates alphavbeta3-CHO cell adhesion through alphavbeta3 integrins
###end title 13
###begin p 14
###xml 195 199 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hsu1">[24]</xref>
###xml 766 768 717 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">25</italic>
###xml 765 769 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Pasco1">[<italic>25</italic>]</xref>
###xml 701 706 <span type="species:ncbi:9606">human</span>
alphavbeta3 is expressed on activated endothelial cells. In addition, inhibition of alphavbeta3 by selective antagonists blocks angiogenesis in response to growth factors in several tumor models [24], indicating that this integrin plays an essential role in tumor growth dependent on angiogenesis. Thus, for all these reasons, we first sought to test the role of alphavbeta3 integrin as a putative receptor to the antiangiogenic factor, CXCL4 and its derived peptide. For this purpose, we used a CHO cells transfected with alphavbeta3 (alphavbeta3-CHO, clone A06) and mock-transfected CHO cells. First, we verified alphavbeta3 expression by flow cytometry using a monoclonal antibody specific for the human alphavbeta3 (LM609). In accordance with our previous data [25], alphavbeta3 integrin is highly expressed in alphavbeta3-CHO cells whereas control mock-transfected CHO cells are negative for alphavbeta3 expression (data not shown).
###end p 14
###begin title 15
Immobilized CXCL4 or CXCL4/CTF supported alphavbeta3-CHO but not CHO adhesion, in a saturable and concentration-dependent manner
###end title 15
###begin p 16
###xml 106 107 99 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 213 220 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g002">Fig. 2A</xref>
###xml 241 247 234 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g002">Fig 2B</xref>
###xml 447 448 419 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 697 698 655 656 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 731 738 689 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g002">Fig. 2B</xref>
###xml 847 851 805 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Humphries1">[26]</xref>
###xml 954 961 912 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g002">Fig. 2C</xref>
###xml 1044 1045 995 996 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 1175 1176 1119 1120 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 1258 1265 1202 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g002">Fig. 2B</xref>
###xml 1326 1327 1263 1264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 1473 1474 1396 1397 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
###xml 1579 1580 1488 1489 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</bold>
Quantitative cell attachment assays demonstrated that immobilized CXCL4 or CXCL4/CTF supported alphavbeta3-CHO cell adhesion, but not mock-transfected CHO cells, in a saturable and concentration-dependent manner (Fig. 2A). Also, as shown in Fig 2B, adhesion to CXCL4 or CXCL4/CTF was significantly inhibited by monoclonal antibodies LM609, AV1 and B3A against alphavbeta3, alphav and beta3, respectively. These results demonstrate that alphavbeta3-CHO adhesion on immobilized CXCL4 or CXCL4/CTF is mediated by alphavbeta3 integrin. Consistent with these results, addition of 10 mM of EDTA, a strong inhibitor of divalent cation-dependent cell integrin receptors, blocks the adhesion of alphavbeta3-CHO cells to CXCL4 or CXCL4/CTF (Fig. 2B). Furthermore, the incubation of cells with two well established cation activators integrins, Mn2+ and Mg2+ [26], prior to adhesion of cells to immobilized CXCL4 or CXCL4/CTF enhances the cell attachment about 25% (Fig. 2C). These findings indicate that immobilized CXCL4 or CXCL4/CTF mediates alphavbeta3-CHO cell adhesion in a divalent cation-dependent manner. As with EDTA, addition of RGD-peptides blocks the adhesion of alphavbeta3-CHO to CXCL4 or CXCL4/CTF, whereas control RGE peptide had no affect on adhesion (Fig. 2B). These findings suggest that the interaction of alphavbeta3-CHO cells with CXCL4 or -CXCL4/CTF is RGD-dependent. This is consistent with the idea that alphavbeta3 integrin is a CXCL4 receptor in alphavbeta3-CHO cells, since alphavbeta3 is RGD dependent. Taken together, these results demonstrate that alphavbeta3-CHO cells attachment on immobilized CXCL4 or CXCL4/CTF is a cation-dependent process and is alphavbeta3 integrin mediated.
###end p 16
###begin title 17
CXCL4 or CXCL4/CTF mediates alphavbeta3-CHO cell adhesion through alphavbeta3 integrins.
###end title 17
###begin p 18
###xml 265 285 251 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Material and Methods</italic>
###xml 265 285 251 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref>
In A. Dose dependence of alphavbeta3-CHO cell adhesion to CXCL4 or CXCL4/CTF. alphavbeta3-CHO and mock-transfected CHO were plated onto microtiter wells coated with the indicated concentrations of CXCL4 or CXCL4/CTF and cell attachment was analyzed as described in Material and Methods. In B, alphavbeta3-CHO adhesion to CXCL4 or CXCL4/CTF is alphavbeta3 integrin-dependent. Cells were incubated with the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or CXCL4/CTF. Anti-integrin antibodies used were: anti-alphavbeta3 (LM609), anti-alphav (AlphaV1), anti-beta3 (B3A). Cell attachment was analyzed as above. Error bars represent the mean+/-SD, *, P</=0.001; **, P</=0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n = 4 independent experiments. In C, adhesion of alphavbeta3-CHO to immobilized CXCL4 or CXCL4/CTF is cation-dependent manner. The serum free medium used for the adhesion assay contained 0.25 mM of Mn2+, or 2 mM of Mg2+. Cell attachment was analyzed as above. Error bars represent the mean+/-SD, *, P</=0.005 compared to CXCL4 or CXCL4/CTF alone; n = 4 independent experiments.
###end p 18
###begin title 19
CXCL4 and CXCL4/CTF bind to purified integrins
###end title 19
###begin p 20
###xml 150 154 150 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Rehn1">[27]</xref>
###xml 199 200 192 193 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(</bold>
###xml 222 229 215 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g003">Fig. 3A</xref>
###xml 565 572 537 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g003">Fig. 3B</xref>
###xml 172 177 <span type="species:ncbi:9606">human</span>
To reinforce the results described above, we studied the direct interaction of CXCL4, or CXCL4/CTF, to integrin in a solid-phase ligand binding assay [27] using a purified human integrin alphavbeta3 (protein). As shown in Fig. 3A, soluble alphavbeta3 demonstrates a concentration- dependent and saturable binding to immobilized CXCL4 or its peptide CXCL4/CTF. The specificity of the interaction was confirmed by inhibition of CXCL4 or CXCL4/CTF binding to alphavbeta3 integrin with the inhibitory alphav (AV1) and beta3 (B3A) antibodies, as well with RGD peptides (Fig. 3B). Thus, these results demonstrate a specific and direct interaction between the angiogenic inhibitor CXCL4 or its peptide CXCL4/CTF with the alphavbeta3 integrin.
###end p 20
###begin title 21
CXCL4 or CXCL4/CTF binds to purified alphavbeta3 integrins in a concentration-dependent and specific manners in solid-phase ligand binding assay.
###end title 21
###begin p 22
###xml 170 176 <span type="species:ncbi:9986">rabbit</span>
Alpha. alphavbeta3 integrin was added to wells coated with CXCL4 or CXCL4/CTF as indicated, and incubated overnight at 4degreesC. Anti-alphav, peroxidase-conjugated anti-rabbit IgG antibodies, and TMB substrate were used to detect bound integrin. B. Soluble RGD-, RGE peptides or inhibitory anti-integrin antibodies were added to block the interaction between CXCL4 or CXCL4/CTF and alphavbeta3 integrin. Bound integrin was detected as above. Anti-integrin antibodies used were: anti-alphav (AV1) and anti-beta3 (B3A). Error bars represent the mean+/-SD, *, P</=0.005; **, P</=0,0005 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n = 3 independent experiments.
###end p 22
###begin title 23
Immobilized CXCL4 or CXCL4/CTF promotes alphavbeta3-CHO cell spreading
###end title 23
###begin p 24
###xml 146 152 139 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g004">Fig. 4</xref>
###xml 579 585 558 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g004">Fig. 4</xref>
Confocal analysis showed that immobilized CXCL4 or CXCL4/CTF promoted alphavbeta3-CHO cell spreading, focal adhesion and stress fibers formation (Fig. 4). These events were blocked in presence of EDTA or RGD peptides or with antibodies against alphavbeta3. In contrast, mock-transfected CHO cells did not appreciably spread and generate stress fibers of actin on CXCL4 or CXCL4/CTF. In addition, when alphavbeta3-CHO cells are plated on a scrambled peptide derived (CXCL4CTF-S), or on polylysine, they remained round, and failed to spread and to induce focal adhesion formation (Fig. 4). These results indicate that immobilized CXCL4 or CXCL4/CTF induces alphavbeta3-CHO cell spreading through alphavbeta3 integrins. Collectively, these results show that CXCL4 or CXCL4/CTF interacts with alphavbeta3 integrins and activates postligand binding event downstream to integrins, such as cell spreading.
###end p 24
###begin title 25
Immobilized CXCL4 or CXCL4/CTF promotes alphavbeta3-CHO cell spreading, focal adhesion and stress fiber formation.
###end title 25
###begin p 26
A. alphavbeta3-CHO and mock-transfected CHO cells were plated for 4 h on coverslips that had been coated with (25 microg/ml) CXCL4, (25 microg/ml) CXCL4/CTF, (25 microg/ml) CXCL4/CTF-S, (100 microg/ml) fibrinogen and (100 microg/ml) poly-D-lysine. After washing, the cells are fixed. The degree of cell spreading is seen from the phase contrast micrographs (left side). Then the cells were permeabilized and stained to visualize focal adhesion (vinculin staining, green), and actin stress fibers (Rhodamin-Phalloidin staining, red) by confocal microscopy (right side). B. Effects of function-blocking anti-integrin antibodies and EDTA and RGD-, RGE-peptides on cell spreading to CXCL4 or CXCL4/CTF. alphavbeta3-CHO cells were incubated with 10 mM EDTA or 25 microg/ml of RGD- or RGE-peptides or 10 microg/ml anti-alphavbeta3 (LM609), before plating to coverslips coated with (25 microg/ml) CXCL4 or (25 microg/ml) CXCL4/CTF for 3 h at 37degreesC. Wells were washed with PBS, and cells were photographed.
###end p 26
###begin title 27
###xml 2 7 <span type="species:ncbi:9606">Human</span>
3/Human endothelial cells (HUVECS) adhere on immobilized CXCL4-, or CXCL4/CTF- through alphavbeta3, and additional integrins, alphavbeta5 and alpha5beta1
###end title 27
###begin p 28
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Trikha1">[28]</xref>
###xml 569 576 527 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5A</xref>
###xml 720 727 657 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5B</xref>
###xml 1107 1114 1030 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>
###xml 1310 1317 1212 1219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>
###xml 427 432 <span type="species:ncbi:9606">human</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 984 989 <span type="species:ncbi:9606">human</span>
To investigate the interaction of CXCL4 or CXCL4/CTF with endogenous integrins, we tested the interaction of CXCL4 or CXCL4/CTF with integrins expressed on the surface of cultured HUVECs. We first screened the expression of endogenous integrins using a flow cytometry analysis. Accordingly with previous data [28], we found that alphavbeta3, alphavbeta5 and alpha5beta1 were constitutively expressed on HUVECs cells using anti-human integrin antibodies specific for human integrin antibodies specific for alphavbeta3 (LM609), alphavbeta5 (P1F6), and alpha5beta1 (HA5) (Fig. 5A). We next studied whether alphavbeta3, alphavbeta5 and alpha5beta1 integrins expressed on HUVECs could bind to CXCL4 or CXCL4/CTF. As shown in Fig. 5B, immobilized CXCL4 or CXCL4/CTF supported HUVECs cell adhesion in a saturable and concentration-dependent manner. Adhesion to CXCL4 or CXCL4/CTF was blocked in presence of RGD peptides or with antibodies against alphavbeta3, thus confirming as above, that human endothelial cells adhere to immobilized CXCL4 or CXCL4/CTF through alphavbeta3 integrins in an RGD dependent manner (Fig. 5C). Interestingly, blocking antibodies against alphavbeta5 (P1F6) and alpha5beta1 (JBS5), as with alphavbeta3, significantly reduced the adhesion of HUVECs cells on immobilized CXCL4 or CXCL4/CTF (Fig. 5C). In contrast, blocking antibody against alpha2beta1-integrin did not affect cell adhesion on immobilized CXCL4 or CXCL4/CTF (data not shown). Thus, these results demonstrate that endothelial cells adhere to immobilized CXCL4 or CXCL4/CTF through alphavbeta3, and other integrins, alphavbeta5 and alpha5beta1, which play a crucial role in angiogenesis.
###end p 28
###begin title 29
CXCL4-, or CXCL4/CTF-integrin mediates HUVECs adhesion through endogen alphavbeta3, alphavbeta5 and alpha5beta1 integrins.
###end title 29
###begin p 30
###xml 293 314 272 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</italic>
###xml 293 314 272 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4"><italic>Materials and Methods</italic></xref>
###xml 625 645 598 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Material and Methods</italic>
###xml 625 645 598 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref>
A. Expression profile of integrins in HUVECs cells analyzed by flow cytometry. HUVECs were incubated with primary antibodies specific for alphavbeta3 (LM609), or alphavbeta5 (P1F6), or alpha5beta1 (HA5) and antibody binding was detected with FITC-labeled secondary antibody as described under Materials and Methods. Cells stained with secondary antibody (2degrees Ab) only were used as a negative control. B. Dose dependence of HUVECs cell adhesion to CXCL4 or CXCL4/CTF. HUVECs were plated onto microtiter wells coated with the indicated concentrations of CXCL4 or CXCL4/CTF and cell attachment was analyzed as described in Material and Methods C. Cell adhesion to CXCL4 and CXCL4/CTF is alphavbeta3, alphavbeta5 and alpha5beta1 integrins dependent. Cells were incubated with the indicated antibodies or RGD-, RGE peptides before plating to wells coated with CXCL4 or CXCL4/CTF. Anti-integrin antibodies used were: anti-alphavbeta3 (LM609), anti-alphav (AlphaV1), anti-beta3 (B3A), anti-alphavbeta5 (P1F6), anti-alpha5beta1 (JBS5), anti-alpha5 (P1D6) and anti-beta1 (CD29). Cell attachment was analyzed as above. Error bars represent the mean+/-SD, *, P</=0.001; **, P</=0,0001; #, P</=0,00001 compared to CXCL4 or CXCL4/CTF in the presence of IgM control antibody; n = 4 independent experiments.
###end p 30
###begin title 31
4/Integrin agonists, Mn2+ and PMA, enhance cell spreading, with focal adhesion and stress fibers formation, on immobilized CXCL4 or CXCL4/CTF
###end title 31
###begin p 32
###xml 296 302 296 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g004">4</xref>
###xml 746 752 746 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>
###xml 954 960 954 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>
###xml 1098 1102 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Pampoori1">[29]</xref>
###xml 1161 1165 1140 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Vuori1">[30]</xref>
###xml 1167 1171 1146 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Mould1">[31]</xref>
###xml 1349 1355 1324 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g006">Fig. 6</xref>
###xml 1626 1629 1601 1604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">see</italic>
###xml 1629 1639 1604 1614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Discussion</italic>
###xml 1629 1639 1604 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s3"><italic>Discussion</italic></xref>
To further examine the postligand events downstream to integrins induced by immobilized CXCL4 or CXCL4/CTF, we examined in more detail cell spreading. As shown above, confocal analysis shows that immobilized CXCL4 or CXCL4/CTF promoted cell spreading, focal adhesion and stress fibers formation (Fig. 1,4). When the number of cells spread on different immobilized substrates was quantified, we found that immobilized CXCL4 or CXCL4/CTF promoted cell spreading by about 50 to 60% in the absence of integrin agonists. When we analyzed the spreaded cells by confocal microscopic we found that around 40% of these cells spread on CXCL4 or CXCL4/CTF (versus 60% with fibronectin, data not shown) presented focal adhesions with stress fiber formation (Fig. 6). These events were significantly increased (from 40% to 60%) when we added two-well known integrin activators, extracellular (Mn2+) and intracellular (Phorbol 12-Mryristate 13 Acetate (PMA) agonists (Fig. 6). These agonists activate alphavbeta3 integrin (convert alphavbeta3 to a high-affinity conformation) and stimulate alphavbeta3 functions [29], such spreading cells, as well as that of other integrins [30], [31]. Incubation of cells with 250 microM of Mn2+ or 100 nM of PMA produced an increase in both the number of attached cells and in cell spreading of about 25% and 30% respectively (Fig. 6). This enhancement was completely blocked by adding EDTA or RGD (data not shown). This finding suggests that the interaction of CXCL4 or CXCL4/CTF to integrins, similar to natural integrin ligands, is subject to integrin function regulation such as affinity modulation (seeDiscussion).
###end p 32
###begin title 33
Integrin agonists, Mn2+ and PMA, enhance cell spreading, with focal adhesion and stress fiber formation, on immobilized CXCL4 or CXCL4/CTF A, B.
###end title 33
###begin p 34
a. Phase contrast analysis show an enhance of the number of alphavbeta3-CHO and HUVECs spreading on immobilized CXCL4 or CXCL4/CTF, upon stimulation with Mn2+ or PMA, b. Confocal analysis show an increase of the number of cell spreading with focal adhesion (Vinculin staining, green) and stress fibers (Rhodamin-Phalloidin staining, Red) formation in alphavbeta3-CHO and HUVECs spread on immobilized CXCL4 or CXCL4/CTF treated with integrin stimulators, Mn2+ or PMA, as compared with no agonists. C. 100 adherent cells on different substrat were scored for focal adhesions and stress fibers by two independent observers. Data are the means+/-SEM of 4 separate experiments. Error bars represent the mean+/-SD, *, P</=0.005 compared to CXCL4 or CXCL4/CTF in the absence of integrin agonists.
###end p 34
###begin title 35
5/The ability of CXCL4 to bind to integrin is related to its anti-angiogenic action
###end title 35
###begin p 36
###xml 90 94 90 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Lozano1">[32]</xref>
###xml 421 427 414 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g001">Fig. 1</xref>
###xml 428 429 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g004">4</xref>
###xml 603 610 596 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g006">Fig. 6C</xref>
The scrambled control peptide CXCL4/CTF-S fails to inhibit endothelial cell proliferation [32]. We thus tested whether this inactive peptide could bind to integrins. We found that, in contrast with CXCL4/CTF and similar to polylysine, alphavbeta3-CHO or HUVECs plated on immobilized CXCL4/CTF-S peptide did not adhere significantly. Cells remained round and failed to assemble focal adhesion and to induce stress fibers (Fig. 1,4). The addition of the two integrin activators, Mn2+ and PMA, had no effect on the number of attached cells or on cell spreading on PF-4/CTF-S as shown by confocal analysis (Fig. 6C). These results suggest that the ability of CXCL4 and CXCL4/CTF to bind integrins is correlated with their anti-angiogenic activity.
###end p 36
###begin title 37
6/Soluble CXCL4 or CXCL4/CTF inhibits cell adhesion to immobilized fibronectin and vitronectin
###end title 37
###begin p 38
###xml 498 505 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0002657.s001">Fig. S1</xref>
To investigate whether CXCL4 or CXCL4/CTF could inhibits cell adhesion to integrin ligands, we tested the effect of soluble CXCL4 or CXCL4/CTF on alphavbeta3-CHO and HUVECs cells adhesion to specific alphavbeta3 and alpha5beta1 ligands, vitronectin and fibronectin respectively. We found that the pre-incubation of cells with soluble CXCL4 or CXCL4/CTF induces cell rounding, and significantly inhibits cell adhesion to immobilized fibronectin and vitronectin, in a concentration-dependent manner (Fig. S1). CXCL4 or CXCL4/CTF did not affect cell adhesion to collagen I (data not shown). These results suggest that soluble CXCL4 and CXCL4/CTF act as antagonists of alphavbeta3 and alpha5beta1 integrins to their ligands.
###end p 38
###begin title 39
7/immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin-dependent and -specific manners
###end title 39
###begin p 40
###xml 64 68 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Davis1">[13]</xref>
###xml 195 203 195 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 203 206 203 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Yoshida1">[33]</xref>
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 319 323 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Byzova1">[34]</xref>
###xml 341 345 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Kim1">[17]</xref>
###xml 753 757 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Davis1">[13]</xref>
###xml 800 807 758 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7A</xref>
###xml 960 967 904 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7A</xref>
###xml 1018 1021 962 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 1023 1027 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Yoshida1">[33]</xref>
Cell migration is an essential step in the angiogenesis process [13]. Previous studies showed that CXCL4 or CXCL4/CTF block endothelial cell migration in response to FGF-2 or VEGF in stimulation in vitro[7], [33], a process thought to mediate the anti-angiogenic effect of CXCL4 in vivo. On the other hand, alphavbeta3 [34], and alpha5beta1 [17] integrins have a crucial role in cell migration during angiogenesis. Taking into account our findings, we determined whether CXCL4 and its antiangiogenic derived peptide modulates endothelial cell migration through alphavbeta3 and/or alpha5beta1 integrins. Our finding showed that soluble CXCL4 or CXCL4/CTF inhibited HUVECs cells migration through fibronectin a reported alphavbeta3 and alpha5beta1 ligand [13], toward VEGF, in a dose depending manner (Fig. 7A). This migration is similarly inhibited by adding RGD peptides or by the blocking integrin antibodies, anti-alphavbeta3 LM609 or anti-alpha5beta1 JBS5 (Fig. 7A). These results are consistent with previous data [7], [33], and suggest that CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin dependent manner.
###end p 40
###begin title 41
Immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits integrin-dependent endothelial cell migration.
###end title 41
###begin p 42
###xml 359 379 340 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Material and Methods</italic>
###xml 359 379 340 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4"><italic>Material and Methods</italic></xref>
###xml 514 515 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
###xml 1672 1673 1619 1620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
A. Soluble CXCL4 or CXCL4/CTF inhibits migration on fibronectin toward VEGF (5 ng/ml). HUVECs migration was determined in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S or 25 microg/ml of RGD-, RGE peptides or 10 microg/ml of anti-integrin antibodies (anti-alphav; AV1 and anti-alpha5beta1; JBS5) as described in Material and Methods. Relative cell migration is indicated, each value is a mean+/-SEM from 3 independent experiments. Error bars represent the mean+/-SD, #, P</=0.05; *, P</=0.005, **, P</=0.001 compared to the number of cell migrated in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides. B. Immobilized CXCL4 or CXCL4/CTF supports HUVECs migration in alphavbeta3 and alpha5beta1 integrins-dependent manner. Cell migration assay was performed on immobilized CXCL4 or CXCL4/CTF in serum free medium and in the presence or absence of inhibitory anti-integrin antibodies or RGD-, RGE peptides. The results at each point are the mean cell number of 10 randomly selected high magnification microscopic fields. Error bars represent the mean+/-SD, *, P</=0.005; *, P</=0.001 compared to CXCL4 or CXCL4/CTF in the presence of IgG control antibody; n = 3 independent experiments. C. Soluble CXCL4 or CXCL4/CTF inhibits migration on fibronectin. HUVECs migration was determined in serum free medium and in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S or inhibitory anti-integrin antibodies or RGD-, RGE peptides. Relative cell migration is indicated, each value is a mean+/-SEM from 3 independent experiments. Error bars represent the mean+/-SD, #, P</=0.005; *, P</=0.001 compared to the number of cell migrated in the absence of CXCL4 or CXCL4/CTF or anti-integrin antibodies or RGD peptides.
###end p 42
###begin p 43
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Leavesley1">[22]</xref>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Leavesley1">[22]</xref>
###xml 1108 1115 1094 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7B</xref>
###xml 1264 1271 1243 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7B</xref>
###xml 1375 1382 1354 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7C</xref>
###xml 1696 1703 1664 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g007">Fig. 7C</xref>
To study the functional significance of the specific CXCL4-integrin interaction, we examined the capacity of CXCL4 to modulate cells functions under conditions in which these functions are strictly dependent on integrins, and not any other agents. For this purpose, we use a haptotactic Boyden chamber assay to assess cell migration in the absence of growth factors, or other soluble chemoattractants (such as VEGF). Using this assay, previous data showed that immobilized integrin inhibitors act as functional agonists and similarly promote integrin functions as cell migration [22]. On the other hand, cell migration is efficiently inhibited by the same integrin inhibitors when given in solution to the cells [22]. We demonstrated that CXCL4 or CXCL4/CTF is similarly capable of modulating endothelial cell migration. Thus, HUVEC cells under serum free-medium migrated in a haptotactic Boyden chamber assay through a CXCL4- or CXCL4/CTF-coated membrane and this migration was significantly inhibited by RGD peptides or by the blocking integrin antibodies, anti-alphavbeta3 LM609 or anti-alpha5beta1 JBS5 (Fig. 7B). In control experiments, blocking antibody against alpha2beta1-integrin did not affect cell migration through CXCL4- or CXCL4/CTF-coated membrane (Fig. 7B). Soluble CXCL4 or CXCL4/CTF, in turn, interferes with integrin-dependent cell migration. As shown in (Fig. 7C), soluble CXCL4 or CXCL4/CTF, but not the inactive peptide CXCL4/CTF-S, inhibited cell migration on immobilized fibronectin, in a concentration-dependent manner. In control experiments, RGD peptides or blocking antibodies against alphav or alpha5beta1-integrin inhibited endothelial cell motility on fibronectin (Fig. 7C). Soluble CXCL4 and CXCL4/CTF, or antibodies against alphav and alpha5beta1 integrins, did not affect cell migration on collagen I, on which the cells migrated in a manner dependent on non-RGD binding beta1 integrins (data not shown). Thus, immobilized CXCL4 or CXCL4/CTF promotes and soluble CXCL4 or CXCL4/CTF inhibits endothelial cell migration in an integrin-dependent and -specific manners.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 251 253 251 253 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1)</bold>
###xml 361 363 340 342 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2)</bold>
###xml 500 502 472 474 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3)</bold>
###xml 641 642 606 607 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</bold>
###xml 795 797 753 755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5)</bold>
We sought to assess whether CXCL4, a CXC chemokine that exhibit potent anti-angiogenic activities, and its C-terminus derived peptide CXCL4/CTF, would function as ligands for the integrin receptors on the surface of endothelial cells. We report here (1) that CXCL4 or CXCL4/CTF binds to alphavbeta3 and to some extent to alphavbeta5 and alpha5beta1 integrins. (2) CXCL4 or CXCL4/CTF binding to integrins on the surface of alphavbeta3-CHO and HUVECs is blocked by RGD peptide but not by RGE peptide. (3) The inactive peptide derived from CXCL4/CTF (CXCL4/CTF-S), fails to interact with integrins on the surface of alphavbeta3-CHO or HUVECs. (4) Immobilized CXCL4 or CXCL4/CTF promotes alphavbeta3-CHO and HUVEC cells spreading, focal adhesion and stress fibers formation and FAK phosphorylation (5) Functional studies show that immobilized CXCL4- or CXCL4/CTF support endothelial cells migration in an integrin-dependent manner and soluble CXCL4 or CXCL4/CTF, in turn, inhibits integrin-dependent endothelial cell migration.
###end p 45
###begin p 46
Thus, the present study is the first to show that CXCL4 interacts with integrins. This interaction may constitute a novel mechanism for the inhibitory effects of CXCL4 on angiogenic blood vessels.
###end p 46
###begin p 47
###xml 601 605 587 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Rehn1">[27]</xref>
###xml 616 620 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sudhakar1">[35]</xref>
###xml 631 635 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Magnon1">[36]</xref>
###xml 650 654 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sudhakar2">[37]</xref>
###xml 656 660 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Maeshima1">[38]</xref>
###xml 1363 1367 1314 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Koivunen1">[39]</xref>
###xml 1369 1373 1320 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Koivunen2">[40]</xref>
###xml 1587 1594 1538 1545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1642 1646 1593 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Arap1">[41]</xref>
Several lines of cell biological and biochemical evidence demonstrated the interaction between CXCL4 and integrins in our study. Thus, inhibitory anti-integrin antibodies prevented alphavbeta3-CHO and HUVEC cell attachment whereas CXCL4 interacted directly with purified alphavbeta3 integrin in a specific manner in a solid-phase binding assay. Despite the fact that neither CXCL4 nor CXCL4/CTF contain an RGD sequence, the interaction of CXCL4 with integrins is divalent cation-dependent and is blocked by RGD peptide. Interestingly, a number of endogenous angiogenesis inhibitors such as endostatin [27], arresten [35] canstatin [36] and tumstatin [37], [38] also bind directly to integrin, despite the fact that they lack the RGD-binding site. For example, the interaction of endostatin with alpha5beta1 integrin is inhibited by RGD peptide, however tumstatin binds to alphavbeta3 in an RGD-independent manner. The fact that the interaction of CXCL4 with integrins is blocked by the RGD peptide indicates that CXCL4 interacts with the same or an overlapping RGD-binding site in integrin. Alternatively, it is possible that other amino acid sequences within CXCL4 also interact with the RGD binding site. Interestingly, CXCL4 and CXCL4/CTF both contain the NGR sequence that is known to interact with integrins, such as alphavbeta3, alphavbeta5 and alpha5beta1 [39], [40]. The NGR motif homes to the tumor vasculature, but not in normal endothelium, through its interaction with integrins. As a consequence, when coupled to anticancer drugs, the NGR peptide was shown to enhance their in vivo anti-tumor action and to reduce their toxicity [41]. Additional studies are required to determine the sequence motif of CXCL4 that integrins recognize.
###end p 47
###begin p 48
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Schwartz1">[21]</xref>
###xml 1046 1050 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Pampoori1">[29]</xref>
###xml 1564 1568 1522 1526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Pampoori1">[29]</xref>
###xml 1640 1644 1598 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-FeldingHabermann1">[42]</xref>
###xml 1620 1625 <span type="species:ncbi:9606">human</span>
Our results show that immobilized CXCL4 or CXCL4/CTF supported cell spreading, focal adhesion and stress fibers formation and tyrosine phosphorylation (i.e., activation) of the focal adhesion kinase (FAK). These events are specific to integrin signaling [21]. This indicates that immobilized CXCL4 or CXCL4/CTF activates postligand binding events downstream of integrins. The addition of two well-known integrin activators, Mn2+ -acting as integrin activator from outside the cells (referred to as outside/in signaling)- and PMA -activating integrins from inside the cells via activation of PKC (referred to as inside/out signaling)-, produced a strong increase in both the number of attached cells and cell spreading on immobilized CXCL4 or CXCL4/CTF, comparable to fibrinogen. Thus, PF4 seems to bind to alphavbeta3 integrins as a natural ligand of alphavbeta3, such as fibrinogen, which binds with low affinity to unstimulated alphavbeta3 and binds with high affinity to activated alphavbeta3 upon stimulation by agonists, such as Mn2+ or PMA [29]. Thus, our finding suggests that interaction of CXCL4 or CXCL4/CTF to integrins is subject to integrin function regulation (i.e. affinity modulation). These results may be relevant to the antiangiogenic activity of CXCL4 in some pathophysiological circumstances in vivo. Indeed, it was shown that the basal activation state of alphavbeta3 varies with the cell type and that an increase in the number of active alphavbeta3 with high affinity for their ligands is correlated with the acquisition of cell malignancy [29] and with the metastasis of some cancer, such as in human breast cancer [42]. Considering that the binding of CXCL4 to integrins depends on the integrin state (active or not), our results suggest that the binding of CXCL4 to endothelial cells should increase during pathological angiogenesis, where affinity modulation of integrins occurs.
###end p 48
###begin p 49
Our results show that soluble CXCL4 or CXCL4/CTF inhibited endothelial cell adhesion to immobilized matrix proteins, as fibronectin or vitronectin. These results suggest that soluble CXCL4 or CXCL4/CTF act as antagonist for integrins alphavbeta3 and alpha5beta1, to mediate its inhibition effect on -endothelial cells adhesion- angiogenesis. Theoretically, it is possible that CXCL4 could also act on attached endothelial cells by further promoting spreading. However, we clearly demonstrated that surface immobilized but not soluble CXCL4 promoted spreading. This finding argues against a similar effect on already attached cells. In addition, it is unlikely that spreading of already attached endothelial cells is inhibited by CXCL4, because of the strong binding of integrins to matrix proteins.
###end p 49
###begin p 50
###xml 62 69 55 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5A</xref>
###xml 294 301 252 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002657-g005">Fig. 5C</xref>
Although alpha5beta1 is the most abundant integrin on HUVECS (Fig. 5A), adhesion experiments on immobilized CXCL4 in the presence of different blocking antibodies against alphavbeta3, alpha5beta1, beta1, alpha5, alphav, beta3 may suggest a greater interaction of CXCL4 to alphavbeta3 integrin (Fig. 5C). However this conclusion must be interpreted with caution because these differences may also be due to more efficiency antibody binding to alphavbeta3 than to alpha5beta1. Also, a quantitative analysis comparing affinities is required to ascertain the potentially better interaction of CXCL4 to alphavbeta3. Nevertheless, assuming that CXCL4 interacts better with alphavbeta3 than alpha5beta1, we may speculate that CXCL4 contains additional sequences for alphavbeta3 interaction. The expression of both integrins alphavbeta3 and alpha5beta1 are significantly up-regulated on endothelial during angiogenesis. While alpha5beta1 selectively recognizes primarily a single ECM protein ligand, fibronectin, alphavbeta3 can bind several ligands such as vitronectin, fibronectin, fibrinogen, and other matrix proteins (13). The fact that CXCL4 may be a better ligand for alphavbeta3 than alpha5beta1, thus blocking the interaction of alphavbeta3 integrin to its various ligands, may increase its inhibitory effect on angiogenesis.
###end p 50
###begin p 51
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Davis1">[13]</xref>
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-De1">[43]</xref>
###xml 634 638 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Davis1">[13]</xref>
###xml 769 772 769 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hagedorn1">[7]</xref>
###xml 774 778 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Yoshida1">[33]</xref>
###xml 1257 1261 1240 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Rehn1">[27]</xref>
###xml 1263 1267 1246 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Short1">[44]</xref>
###xml 1569 1573 1538 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Byzova1">[34]</xref>
###xml 1655 1659 1617 1621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Ashton1">[45]</xref>
To study the functional significance of the CXCL4-integrin interaction on angiogenesis, we examined the capacity of CXCL4 to modulate endothelial cell migration. We found that CXCL4 modulates endothelial cell migration, in an integrin-dependent and -specific manners. Cell migration is a vital step in the angiogenesis process and is governed by pro-angiogenic factors, such as VEGF and FGF, and integrins [13], [43]. Angiogenic stimulus by growth factors induces an increased expression of integrins in endothelial cells undergoing angiogenesis, thereby leading cells to spread, to migrate and to ultimately form new tubular vessels [13]. Previous studies showed that both CXCL4 and CXCL4/CTF block endothelial cell migration in response to VEGF or FGF growth factors [7], [33]. This action is believed to mediate the anti-angiogenic effect of CXCL4, although its receptor mechanism was not characterized. Here we report that soluble CXCL4 or CXCL4/CTF, but not the inactive peptide CXCL4/CTF-S, inhibits endothelial cell migration in alphavbeta3 and alpha5beta1 in an integrin-dependent and -specific manners. Similarly, endostatin and thrombospondin-1, two endogenous angiogenesis inhibitors, inhibited endothelial cell migration through beta1 integrins [27], [44]. Our results suggest that integrins serve as functional receptors for CXCL4 to mediate its inhibition effect on -endothelial cells migration- angiogenesis. On the other hand, other data indicate that VEGF directly activates integrins and enhance cell migration mediated by alphavbeta3 and alpha5beta1 [34] Furthermore, FGF-2 stimulated endothelial cell migration mediated by alphavbeta3 [45]. Further studies are needed to determine the potential significance of integrin-growth factor receptor cross-talk in CXCL4 action.
###end p 51
###begin p 52
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Lozano1">[32]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Perollet1">[46]</xref>
###xml 303 307 303 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Gengrinovitch1">[47]</xref>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Perollet1">[46]</xref>
###xml 416 420 416 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sato1">[48]</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Lasagni1">[49]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sulpice1">[50]</xref>
###xml 991 995 991 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Hansell1">[19]</xref>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Borgstrom1">[20]</xref>
###xml 1293 1300 1293 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1364 1368 1364 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Arap1">[41]</xref>
###xml 1592 1596 1592 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Gengrinovitch1">[47]</xref>
###xml 1703 1707 1703 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Gentilini1">[51]</xref>
Previous studies showed that CXCL4 and its derived peptide CXCL4/CTF inhibit angiogenesis by interfering with the angiogenic effect of the growth factors FGF and VEGF165, either by directly binding to these angiogenic factors, thereby blocking their interaction with their specific receptors [32], [46]-[47], or by competing with the binding of FGF or VEGF to heparan sulfate proteoglycans on the cell surface [46], [48]. Furthermore, CXCL4 was recently shown to bind to CXC3B, a chemokine receptor isoform that is present in some vascular beds [49]. However, the role of CXC3-B receptors in the anti-angiogenic function of CXCL4 remains to be fully established [50]. Our study suggests a novel additional mechanism for the antiangiogenic effects of CXCL4, which involves direct targeting of vessel through integrins. Since integrins are overexpressed in endothelial cells undergoing angiogenesis, this may explain why, in vivo, CXCL4 tends to preferentially target angiogenic blood vessels [19], [20]. Furthermore, this targeting mechanism could be useful for selective treatments of cancer by CXCL4. Indeed and as mentioned above, peptides were shown to home selectively in tumor vasculature, through their interaction with integrins, and when coupled to anticancer drugs, they enhanced the in vivo anti-tumor action and reduced the toxicity of anticancer drugs [41]. Finally, integrin-binding of CXCL4 or CXCL4/CTF is also consistent with a heparan sulfate proteoglycan-independent mechanism. Indeed, VEGF121, an endothelial cell mitogen that lacks heparin affinity, is inhibited by CXCL4 [47]. CXCL4 also antagonizes EGF-mediated endothelial cell proliferation independently from glycosaminoglycans [51].
###end p 52
###begin p 53
###xml 147 154 147 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 320 324 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Lozano1">[32]</xref>
###xml 431 435 431 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Perollet1">[46]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Sato1">[48]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Lasagni1">[49]</xref>
###xml 763 770 763 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In summary, a general picture of CXCL4's antiangiogenic mechanisms is emerging from the results described above. CXCL4 inhibits neovascularization in vivo by several distinct, although not necessarily exclusive, mechanisms including direct integrin binding- reported here -, direct interaction with angiogenic molecules [32], binding to proteoheparan sulfate-which acts as low affinity co-receptors for growth factors, such as FGF-[46], [48] or activation of CXCR3-B [49]. These different mechanisms may operate in parallel and in function of the site and/or the type of vessel that undergo angiogenesis. Additional studies will be required to fully understand the significance of integrin binding and other mechanisms involved in CXCL4's antiangiogenic activity in vivo.
###end p 53
###begin title 54
Materials and Methods
###end title 54
###begin title 55
Reagents and Cell Culture
###end title 55
###begin p 56
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 79 85 <span type="species:ncbi:9913">bovine</span>
###xml 186 191 <span type="species:ncbi:9606">human</span>
###xml 485 490 <span type="species:ncbi:9606">human</span>
###xml 700 705 <span type="species:ncbi:10090">Mouse</span>
###xml 808 812 <span type="species:ncbi:9925">goat</span>
###xml 818 823 <span type="species:ncbi:10090">mouse</span>
###xml 866 871 <span type="species:ncbi:10090">Mouse</span>
###xml 888 893 <span type="species:ncbi:9606">human</span>
###xml 978 993 <span type="species:ncbi:10029">Chinese hamster</span>
###xml 1058 1063 <span type="species:ncbi:9606">human</span>
###xml 1262 1268 <span type="species:ncbi:9913">bovine</span>
###xml 1366 1371 <span type="species:ncbi:9606">Human</span>
###xml 1492 1498 <span type="species:ncbi:9913">bovine</span>
Fibronectin from human, plasma Fibrinogen from human plasma, poly-D-lysine and bovine serum albumin (BSA, fraction V) were purchased from Sigma. RGDS and RGES peptides were from Bachem, human purified platelet factor 4/CXCL4 (CXCL4) was obtained from Hyphen BioMed, France. C-terminal peptides of CXCL4, CXCL4/CTF (NGRKICLDLQAPLYKKIIKKLLES) or CXCL4/CTF-S (LGLKPLKQELIAYRDNK IKSICLK) were purchased from ThermoHybaid (Ulm, Germany). Purified integrins and the purified monoclonal anti-human integrin antibodies LM609 (anti-alphavbeta3), P1F6 (anti-alphavbeta5), JBS5 and HA5 (anti-alpha5beta1), B3A (anti-beta3), AV1 (anti-alphav), CD29 (anti-beta1), P1D6 (anti-alpha5) were purchased from Chemicon. Mouse Ig1 antibody was purchased from Chemicon. Peroxidase and FITC (Fluorescein isothiocyanate) conjugated goat anti-mouse immunoglobulins were purchased from DAKO. Mouse monoclonal anti-human vinculin antibody was from Sigma and Rhodamin-Phalloidin from Molecular probes. The Chinese hamster ovary (CHO) cell line CRL9096, as well as CHO clones expressing human alphavbeta3 integrin (alphavbeta3-CHO, A06) were established as described (25). Cells lines were grown at 37degreesC, 5% CO2 in Dublecco's Modified Eagle Medium (GIBCO) supplemented with 10% foetal bovine serum, 2 mM glutamine, penicillin and streptomycin (100 UI/ml) and 1% non-essential amino acids. Human umbilical vein endothelial cells (HUVECs, Clonetics) were cultured in EGM medium (Cambrex) supplemented with 10% foetal bovine serum, 2 mM glutamine, and penicillin and streptomycin (100 UI/ml). Experimentation was carried out at cell passage number 4-10.
###end p 56
###begin title 57
Flow Cytometry
###end title 57
###begin p 58
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Pampoori1">[29]</xref>
###xml 159 160 159 160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 162 163 162 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 476 480 <span type="species:ncbi:9925">goat</span>
###xml 486 491 <span type="species:ncbi:10090">mouse</span>
Analysis cell-surface integrin expression was performed as described [29]. Cells were suspended in incubation Walsh buffer (137 mM NaCl, 2.7 mM KCL, 3.3 mM NaH2PO4, 3.8 mM HEPES, 1 mM MgCl2, 5.5 mM glucose, and 1 mg/ml BSA, pH 7.4) and 2x105 cells incubated for 30 min on ice with a monoclonal antibody (10 microg/ml) specific for alphavbeta3 (LM609), or alphavbeta5 (P1F6), or alpha5beta1 (HA5). After washing, the cells were incubated for 20 min on ice with FITC-conjugated goat anti-mouse IgG, washed again, and analyzed on a FACSCalibur flow cytometer (Becton Dickinson Biosciences). As a negative control, samples were incubated with the secondary antibody alone.
###end p 58
###begin title 59
Cell Attachment Assay
###end title 59
###begin p 60
###xml 41 45 41 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Wickstrm1">[52]</xref>
###xml 378 379 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Cell attachment was assayed as described [52]. Microtiter wells (Immulon 2, ThermoLabsystems) were coated for 2 h at 37degreesC with the indicated concentrations of proteins. The wells were blocked for 1 h with 1% BSA in PBS. Cells were briefly trypsinized followed by washes with serum-containing medium and serum-free medium containing 0,5% BSA. Cells were suspended in 3,5x105 cells/ml in serum-free medium containing 0,5% BSA and incubated in the presence or absence of 10 mM EDTA, 25 microg/ml RGD, RGE peptides or 10 microg/ml of anti-integrin antibodies for 15 min at room temperature. To inhibit adhesion on various ECMs proteins with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior plating onto wells, as indicated in the figures. 100 microl of cells suspensions were added to the coated wells, and the plates were incubated at 37degreesC for 60 min. Non attached cells were removed by washing with PBS and then fixed and stained in 30% methanol, 10% acetic acid, containing 0,1% Coomassie blue. After extensive washing, the cells were lysed in 1% SDS, after which the amount of lysed cells were quantified by measuring their absorbance at 620 nm. Background absorbance observed in the wells coated with BSA was deducted from the values obtained. Each time point represented three independent experiments performed in triplicate.
###end p 60
###begin title 61
Solid-Phase Ligand-Binding Assay
###end title 61
###begin p 62
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Rehn1">[27]</xref>
###xml 889 890 862 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 892 893 865 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 768 772 <span type="species:ncbi:9925">goat</span>
###xml 778 784 <span type="species:ncbi:9986">rabbit</span>
Solid-phase ligand binding assay was performed as described previously with minor modifications [27]. Immulon 2 microtiter wells were coated with 25 microg/ml CXCL4 or CXCL4/CTF in PBS overnight at 4degreesC. The wells were blocked with 1% BSA in walsh buffer at room temperature for 1 h. Octylglucoside alphavbeta3 integrin was added on coated wells and incubated for 2 h at 37degreesC. Unbound integrin molecules were extensively washed with walsh buffer containing 0,05% Tween 20. The bound integrin molecules were incubated with 1/1000 dilution of a polyclonal anti-alphav cytoplasmic domain antibody (Chemicon) for 1 h at room temperature. After extensive washes with walsh buffer-0,05% Tween 20, the bound antibodies were detected by using Peroxidase-Conjugated goat anti-rabbit IgG (Dako). TMB liquid substrate (sigma) was added to the wells, the reactions were stopped with 0,5 M H2SO4, and absorbance was measured at 450 nm. Background absorbance in the wells coated with BSA was deducted from the values obtained.
###end p 62
###begin title 63
Cell Spreading and Confocal Microscopy Analysis
###end title 63
###begin p 64
###xml 539 543 513 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Shiraga1">[53]</xref>
###xml 504 509 <span type="species:ncbi:10090">mouse</span>
Cells were washed twice with serum-free medium, suspended to the serum-free medium, and plated on coverslips that had been coated with (25 microg/ml) CXCL4, (25 microg/ml) CXCL4/CTF, (25 microg/ml) CXCL4/CTF-S, (100 microg/ml) fibrinogen and (100 microg/ml) poly-D-lysine and incubated at 37degreesC for 4 h. After removing nonadherent cells, the adherent cells were fixed in 4% parafolmaldehyde, permeabilized with 0,2% Triton X-100 in PBS, and stained with monoclonal anti-vinculin antibody, FITC-anti-mouse IgG and rhodamine-phalloidin [53]. Cells were analyzed by confocal laser scanning microscopy and photomicrographs were prepared using Adobe Photoshop 8.
###end p 64
###begin title 65
Analysis of Tyrosine Phosphorylation of FAK
###end title 65
###begin p 66
###xml 57 61 57 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Gao1">[54]</xref>
###xml 527 528 511 512 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1003 1009 <span type="species:ncbi:9986">rabbit</span>
Tyrosine Phosphorylation of FAK was assayed as described [54]. HUVECs were plated for 60 min on dishes that had been coated with 5 mg/ml of BSA or (100 microg/ml) fibrinogen or (25 microg/ml) CXCL4 or (25 microg/ml) CXCL4/CTF or (100 microg/ml) poly-D-lysine. After 60 min, non-adherent cells from BSA-coated plates were diluted 1:1 with PBS, sedimented at 100 g for 5 min and washed once with PBS before lysis in complete RIPA buffer (1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 158 mM NaCl, 10 mM Tris, pH 7.4, 1 mM Na2EGTA, 1 mM sodium vanadate, 0.5 mM leupeptin, 0.25 mg/ml pefabloc, 5 mg/ml aprotinin). The adherent cells from plates coated with fibrinogen or CXCL4 or CXCL4/CTF were rinsed twice with PBS, lysed on the plates with ice-cold complete RIPA buffer and scrapped into microcentrifuge tubes. Lysates were incubated for 30 min on ice and clarified supernatants for immunoprecipitation. Equal amounts of protein from each lysate (200 microg of protein) were immunoprecipitated with rabbit antiserum specific for FAK (Santa Cruz). One half of immunoprecipitates were subjected to western blotting with anti-phosphotyrosine mAbs, 4G10 (BD Transduction Laboratories) and PY20 (Upstate Biotechnology), and the other half was probed with mAb anti-FAK (BD Transduction Laboratories). Immunoreactive bands were detected by enhanced cheminuluminescence detection.
###end p 66
###begin title 67
Endothelial cell Migration
###end title 67
###begin p 68
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002657-Leavesley1">[22]</xref>
###xml 376 377 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 671 677 <span type="species:ncbi:3635">cotton</span>
Haptotactic cell motility was measured by using a modified Boyden chamber (BD, Falcon) as previously described [22]. The undersurface of the membrane filter was coated with 25 microg/ml of CXCL4 or 25 microg/ml CXCL4/CTF or various matrix proteins. After washing the membranes with PBS, nonspecific adhesion sites were saturated with 1% BSA at 22degreesC for 1 h. HUVECs (3x104) were added to the upper chambers in serum-free medium and were allowed to migrate to the underside of the chamber for 4 h at 37degreesC. Cell migration was measured after 4 h of incubation at 37degreesC. All non migrated cells were removed from the upper face of the membrane filter with the cotton swab and cells migrated to the lower face were fixed and stained in 30% methanol, 10% acetic acid, containing 0,1% Coomassie blue. Subsequently, the number of stained migrated cells (to the lower face of the membrane filter) was counted. Migration results are expressed in terms of the average number of cells/high-magnification microscopic field. To inhibit migration on CXCL4 or CXCL4/CTF, cells with pretreated with 10 microg/ml of anti-integrin antibodies for 30 min in suspension prior to plated in chambers. To inhibit migration on various matrix proteins with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior adding to the upper chambers, as indicated in the figures. In chemotactic cell motility experiments, VEGF (5 ng/ml) was added in the lower chambers. To inhibit migration on fibronectin to VEGF with soluble CXCL4 or CXCL4/CTF, CXCL4 or CXCL4/CTF were incubated with cells 30 min in suspension prior adding to the upper chambers. In all experiments, nonspecific migration was determined using BSA as a ligand and was subtracted from the values of relative cell migration obtained on different matrix proteins.
###end p 68
###begin title 69
Statistical Analysis
###end title 69
###begin p 70
Student's test was used to determine the significance of differences.
###end p 70
###begin title 71
Supporting Information
###end title 71
###begin p 72
###xml 317 337 302 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Material and Methods</xref>
Soluble CXCL4 or CXCL4/CTF inhibits cell adhesion to fibronectin and vitronectin. HUVECs and alphavbeta3-CHO adhesion on immobilized (10 microg/ml) fibronectin or (10 microg/ml) vitronectin was determined in the presence or absence of the indicated concentrations of CXCL4 or CXCL4/CTF or CXCL4/CTF-S as described in Material and Methods. Error bars represent the mean+SD, #, P<0.005; *, P<0.001 compared to the cell adhesion in the absence of CXCL4 or CXCL4/CTF; n = 2 independent experiments.
###end p 72
###begin p 73
(39.08 MB DOC)
###end p 73
###begin p 74
Click here for additional data file.
###end p 74
###begin p 75
The authors thank Pr Martin A. Schwartz (University of Virginia, Charlottesville, United State) and Dr Serge Ahmed (Universite Victor-Segalen Bordeaux 2) for critically reading the manuscript, Dr Alan Nurden (University Bordeaux II, France) for helpful discussion and Dr Francesca De Giorgi-Ichas, (INSERM U916-Institut Bergonie, Bordeaux) for helpful technical assistance for confocal analysis. This work is dedicated to Aicha Mekki-Aidoudi and Bechir Aidoudi.
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
Angiogenesis in cancer, vascular rheumatoid and other disease.
###end article-title 77
###begin article-title 78
Tumor angiogensis: therapeutic implications.
###end article-title 78
###begin article-title 79
Angiogenesis: an organizing principle for drug discovery?
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human p1atelet factor 4: Purification and characterization by affinity chromatography.
###end article-title 80
###begin article-title 81
###xml 42 47 <span type="species:ncbi:9606">human</span>
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
###end article-title 81
###begin article-title 82
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Modulation of in vitro angiogenesis by platelet factor-4 derived peptides and mechanism of action.
###end article-title 82
###begin article-title 83
A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.
###end article-title 83
###begin article-title 84
###xml 21 27 <span type="species:ncbi:10090">murine</span>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:9606">human</span>
Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4.
###end article-title 84
###begin article-title 85
Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth.
###end article-title 85
###begin article-title 86
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.
###end article-title 86
###begin article-title 87
Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors.
###end article-title 87
###begin article-title 88
###xml 29 35 <span type="species:ncbi:10090">murine</span>
Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
###end article-title 88
###begin article-title 89
Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization.
###end article-title 89
###begin article-title 90
Requirement of vascular integrin alphavbeta3 for angiogenesis.
###end article-title 90
###begin article-title 91
Integrin alphavbeta3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
###end article-title 91
###begin article-title 92
Definition of two angiogenic pathways by distinct alpha v integrins.
###end article-title 92
###begin article-title 93
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin.
###end article-title 93
###begin article-title 94
Platelet secretion.
###end article-title 94
###begin article-title 95
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Selective binding of platelet factor 4 to regions of active angiogenesis in vivo.
###end article-title 95
###begin article-title 96
###xml 56 61 <span type="species:ncbi:9606">human</span>
Recombinant platelet factor 4, an angiogenic marker for human breast carcinoma.
###end article-title 96
###begin article-title 97
Integrins: emerging paradigms of signal transduction.
###end article-title 97
###begin article-title 98
Integrin beta1- and beta3-mediated endothelial cell migration is triggered through distinct signaling mechanisms.
###end article-title 98
###begin article-title 99
Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphavbeta3 during angiogenesis.
###end article-title 99
###begin article-title 100
Integrin alpha (v)beta (3) antagonists for anti-angiogenic cancer treatment.
###end article-title 100
###begin article-title 101
The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alphavbeta3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation.
###end article-title 101
###begin article-title 102
Integrin activation: the link between ligand binding and signal transduction.
###end article-title 102
###begin article-title 103
Interaction of endostatin with integrins implicated in angiogenesis.
###end article-title 103
###begin article-title 104
Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
###end article-title 104
###begin article-title 105
Mechanisms and consequences of affinity modulation of integrin alphavbeta3 detected with a novel patch-enginered monovalent ligand.
###end article-title 105
###begin article-title 106
Activation of protein kinase C precedes alpha5beta1 integrin-mediated cell spreading on fibronectin.
###end article-title 106
###begin article-title 107
Regulation of integrin alpha5beta1-fibronectin interactions by divalent cations. Evidence for distinct classes of binding sites for Mn2+, Mg2+, and Ca2+.
###end article-title 107
###begin article-title 108
###xml 93 98 <span type="species:ncbi:9606">human</span>
Solution structure and interaction with basic and acidic fibroblast growth factor of a 3-kDa human platelet factor-4 fragment with antiangiogenic activity.
###end article-title 108
###begin article-title 109
Differential Endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor.
###end article-title 109
###begin article-title 110
A mechanism for modulation of cellular responses to VEGF: activation of the integrins.
###end article-title 110
###begin article-title 111
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.
###end article-title 111
###begin article-title 112
Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins.
###end article-title 112
###begin article-title 113
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 20 25 <span type="species:ncbi:9606">human</span>
Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alphavbeta3 and alpha5beta1 integrins.
###end article-title 113
###begin article-title 114
Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.
###end article-title 114
###begin article-title 115
Selection of peptides binding to the alpha5beta1 integrin from phage display library.
###end article-title 115
###begin article-title 116
Isolation of a highly specific ligand for the alpha5beta1 integrin from a phage display library.
###end article-title 116
###begin article-title 117
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.
###end article-title 117
###begin article-title 118
###xml 43 48 <span type="species:ncbi:9606">human</span>
Integrin activation controls metastasis in human breast cancer.
###end article-title 118
###begin article-title 119
VEGF-integrin interplay controls tumor growth and vascularization.
###end article-title 119
###begin article-title 120
Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins.
###end article-title 120
###begin article-title 121
Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alphavbeta3.
###end article-title 121
###begin article-title 122
Platelet factor-4 modulates fibroblast growth factor-2 activity and inhibits FGF-2 dimerization.
###end article-title 122
###begin article-title 123
Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.
###end article-title 123
###begin article-title 124
Platelet factor-4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells.
###end article-title 124
###begin article-title 125
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
###end article-title 125
###begin article-title 126
Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms.
###end article-title 126
###begin article-title 127
###xml 14 19 <span type="species:ncbi:9606">human</span>
Inhibition of human umbilical vein endothelial cell proliferation by the CXC chemokine, platelet factor 4 (CXCL4), is associated with impaired downregulation of p21(Cip1/WAF1).
###end article-title 127
###begin article-title 128
An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells.
###end article-title 128
###begin article-title 129
Primary megakaryoctes reveal a role for transcription factor NF-E2 in integrin alphaIIbbeta3 signaling.
###end article-title 129
###begin article-title 130
Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3.
###end article-title 130
###begin p 131
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 131
###begin p 132
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work has been supported by grants from the "Agence Nationale de la Recherche (ANR)", the National French Cancer Institute (INCA), "the Ligue Nationale du Cancer" and the "Association pour la Recherche sur le Cancer (ARC)" to A.B. The sponsors had no role in designing the study or approving the manuscript.
###end p 132

